Adlai Nortye Ltd. filings document foreign private issuer reports for a clinical-stage oncology biotechnology company whose securities trade as American depositary shares. The company’s Form 6-K reports include pipeline disclosures for AN9025, AN4035, AN8025, AN4005 and AN0025; clinical and regulatory updates; unaudited financial results; corporate presentations; and material agreements.
ANL filings also record capital-structure matters, including private-placement securities purchase agreements and ADS-to-Class A ordinary share references, as well as shareholder meeting materials, proxy cards, board and committee changes, executive appointments, and the adoption of a share incentive plan.
Adlai Nortye Ltd. (ANL) reported insider transactions by CFO Ye Xiaofeng. Ye sold a total of 11,667 American Depositary Shares in two open-market transactions: 6,000 ADS on August 24, 2026 at $13.98 per share and 5,667 ADS on August 26, 2026 at a $14.25 weighted average price per share. According to the footnotes, these sales were made solely to optimize the reporting person’s tax and liquidity management after restricted stock units vested on April 14, 2026, where taxes had already been paid in cash, and the proceeds are intended to rebalance personal cash reserves.
Adlai Nortye Ltd. (ANL) is convening an Extraordinary General Meeting of shareholders on September 30, 2026 at 10 a.m. Singapore time in Singapore. Shareholders are asked to approve authority for the directors to allot and issue up to 90,000,000 Class A Ordinary Shares and to waive related pre-emption and similar rights.
Other proposals include re-electing four directors for a three-year term from October 3, 2026 to October 2, 2029, appointing Wanjin Hong as an independent director for the same term, approving specified directors’ remuneration, and authorizing the board to fix auditors’ remuneration for the ensuing year.
Additional items would authorize the board to deal with fractional Class A Ordinary Shares arising from ADS transfers and to adjourn the meeting if there are insufficient votes. The record date is August 28, 2026. Each Class A Ordinary Share carries one vote and each Class B Ordinary Share carries 15 votes. The board recommends voting “FOR” all seven proposals.
Adlai Nortye Group Ltd. (ANL) reports that on July 29, 2026 it completed a corporate reorganization that includes a change of name to “Adlai Nortye Group Ltd.”, a redomiciliation from the Cayman Islands to Singapore, and a move of its registered office to 77 Robinson Road, #20-01, Robinson 77, Singapore 068896, all previously approved by shareholders on December 1, 2025. The company’s ADSs will continue to trade on Nasdaq under the symbol “ANL” and CUSIP 00704R109, with trading under the new name beginning August 21, 2026; existing ADS holders are not required to take any action. Effective August 14, 2026, Boardroom Corporate & Advisory Services Pte. Ltd. became share registrar, with registers and records transferred from the prior Cayman registrar.
The company also adopted a new Singapore-law constitution (Exhibit 99.1) that, among other matters, confirms it as a public company limited by shares and establishes a dual-class structure where each Class A Ordinary Share carries one vote and each Class B Ordinary Share carries fifteen votes, with Class B shares convertible into Class A and subject to automatic conversion to Class A upon transfers that move beneficial ownership outside the founder and his affiliates.
Adlai Nortye Ltd. received an updated beneficial ownership report from a group of Venrock Healthcare entities and individuals Nimish Shah and Bong Koh. As of June 30, 2026, the group reports beneficial ownership of 9,638,193 Class A ordinary shares, equal to 4.4% of the class.
The position is held through 522,711 ADS (1,568,133 shares) by VHCP III, 52,370 ADS (157,110 shares) by VHCP Co‑Investment III, and 2,637,650 ADS (7,912,950 shares) by VHCP EG, with each ADS representing three Class A ordinary shares. The percentage is based on 218,578,430 shares outstanding as of April 21, 2026, and the group indicates ownership of 5 percent or less of the class.
Cormorant Asset Management, LP and Bihua Chen report a significant ownership position in Adlai Nortye Ltd. American Depositary Shares (ADS). They beneficially own 3,978,229 ADS, representing 6.77% of the ADS-equivalent class, with no sole voting or dispositive power and full authority held on a shared basis.
The holding is attributed to investment funds advised by Cormorant, referred to as the Cormorant Funds, with Cormorant Global Healthcare Master Fund, LP entitled to dividends or sale proceeds from more than 5% of the shares. The ownership percentage is calculated using 142,241,572 Class A ordinary shares outstanding as of April 10, 2026, and an additional 11,320,755 ADS sold in a private placement expected to close April 17, 2026.
Adlai Nortye Ltd., a clinical-stage oncology company, reported unaudited results for the six months ended June 30, 2026. Revenue reached US$13.1 million, up from zero a year earlier, entirely from upfront and milestone payments under its AN9025 license agreement with Jiangsu Aosaikang. The company is advancing a global Phase I trial of oral pan-RAS(ON) inhibitor AN9025, obtained first regulatory approval for a Phase I trial of pan-RAS(ON) ADC AN4035, and continues development of immuno-oncology candidates AN8025, AN0025 and AN4005.
As of June 30, 2026, cash and cash equivalents plus short-term investments totaled US$231.9 million, compared with US$8.1 million at December 31, 2025, mainly reflecting strong financing inflows. Net cash used in operating activities was US$15.4 million, similar to the prior-year period. Research and development expenses declined slightly to US$14.6 million, while general and administrative expenses rose to US$5.8 million, largely due to higher share-based compensation. The net loss narrowed to US$5.3 million from US$18.3 million, helped by new collaboration revenue and other operating income. Shareholders’ equity improved from a deficit to US$214.8 million, supported by new share issuances.
Adlai Nortye Ltd. director Lars Erik Birgerson reports a direct holding of 166,668 American Depositary Shares. The position is recorded as a holding entry dated 2026-03-18, with no associated buy or sell transactions and no derivative positions listed.
Adlai Nortye Ltd. announced submission of a Clinical Trial Notification to Australia’s Therapeutic Goods Administration and receipt of Human Research Ethics Committee approval to commence a Phase I clinical trial of AN4035, a CEACAM5-targeting, pan-RAS(ON) inhibitor-based antibody drug conjugate for CEACAM5-enriched, RAS-addicted solid tumors.
The global Phase I study will assess safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of AN4035 as monotherapy and combined with cetuximab. The company describes AN4035 as its first RASiCA™ platform drug and a first-in-class pan-RAS(ON) ADC, supported by preclinical data showing nanomolar to picomolar cytotoxicity, deep tumor regression and a favorable therapeutic index. Adlai Nortye is also preparing IND filings with the U.S. FDA and China NMPA, with patient dosing expected to begin in the second half of 2026.
Adlai Nortye Ltd. updates its resale registration for up to 98,577,627 Class A ordinary shares, represented by 32,859,209 ADSs, by changing how certain shares are attributed among selling shareholders. The change reflects that SILV Fund, Ltd. is now listed as the selling shareholder for 2,307,690 Class A ordinary shares originally shown as held under the February 2026 Private Placement by Point72 Associates, LLC. Point72 continues as a selling shareholder for 2,943,396 Class A ordinary shares from the April 2026 Private Placement. The total number of Class A ordinary shares registered for resale remains unchanged, based on 218,578,430 Class A ordinary shares outstanding as of April 21, 2026. The company’s ADSs trade on Nasdaq under the symbol ANL, and the last reported sale price on July 17, 2026 was US$11.53 per ADS.
Adlai Nortye Ltd. reported dosing the first U.S. patient in the intermittent weekly (QW) arm of its ongoing global Phase 1 trial of AN9025, an oral pan-RAS(ON) inhibitor for advanced or metastatic solid tumors with RAS mutations. With this milestone, both the once-daily (QD) and weekly (QW) dose-escalation arms are enrolling, and the company plans to share initial Phase 1 dose-escalation data from the QD arm in 1H27, with a potential early look at the QW arm.
The first-in-human, multicenter, open-label study evaluates the safety, tolerability, pharmacokinetics and anti-tumor activity of AN9025 and is being run as a multi-regional clinical trial in collaboration with ASK Pharm. Adlai Nortye holds ex-China rights to AN9025, while ASK Pharm retains rights in mainland China, Hong Kong and Macao. AN9025, described as an oral small molecule pan-RAS(ON) inhibitor with best-in-class potential based on preclinical data, is a key part of Adlai Nortye’s broader oncology pipeline alongside additional RAS pathway and PD-1/L1-targeting candidates.